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ABSTRACT
Dysregulation of the 5-HT2A receptor is implicated in both
the etiology and treatment of schizophrenia. Although the
essential role of 5-HT2A receptors in atypical antipsychotic
drug actions is widely accepted, the contribution of 5-HT2A
down-regulation to their efficacy is not known. We hypoth-
esized that down-regulation of cortical 5-HT2A receptors
contributes to the therapeutic action of atypical antipsy-
chotic drugs. To test this hypothesis, we assessed the effect
of chronically administered antipsychotics (clozapine, olan-






and pimavanserin], on the phencyclidine (PCP)-induced hy-
perlocomotor response and cortical 5-HT2A receptor levels in
C57BL/6J mice. Clozapine and olanzapine, but not haloper-
idol, induced receptor down-regulation and attenuated PCP-
induced locomotor responses. Of the selective 5-HT2A an-
tagonists tested, only ketanserin caused significant receptor
protein down-regulation, whereas SR46349B up-regulated
5-HT2A receptors and potentiated PCP-hyperlocomotion; the
other 5-HT2A receptor antagonists were without effect. The
significance of these findings with respect to atypical anti-
psychotic drug action is discussed.
Introduction
According to classic concepts of pharmacology, competitive
receptor antagonists occupy the ligand binding site and “an-
tagonize” receptor activity by precluding agonist binding: “In
competitive antagonism, agonist and antagonist, simultane-
ously present in solution, are each considered to compete for
receptors to the exclusion of the other….” (Stephenson, 1956).
This notion of blockade of G protein-coupled receptor activa-
tion by “steric hindrance” has been supported by recent
crystallographic studies of the -adrenergic receptor, show-
ing that agonists and antagonists occupy overlapping (but
not identical) binding sites (Rosenbaum et al., 2007, 2011;
Warne et al., 2011). The notion that some G protein-coupled
receptor antagonists can also stabilize the inactive state of
the receptor and thereby function as inverse agonists was
first put forth by Costa and Herz (1989) in studies of opioid
receptors. It is now well accepted that so-called antagonists
could have negative intrinsic activity and thus function as
inverse agonists or lack activity and thus function as neutral
antagonists. However, by definition an “antagonist” is devoid
of efficacy.
Contradicting these fundamental notions of pharmacology
have been observations dating to the late 1970s that some
so-called antagonists can display various patterns of efficacy.
Thus, Bergstrom and Kellar (1979) and Peroutka and Snyder
(1980) showed that chronic administration of antidepres-
sants with potent 5-HT2A antagonist activity induces a down-
regulation of 5-HT2A receptor levels. This property was sub-
sequently demonstrated to be shared by a number of drugs
with potent 5-HT2A antagonist activity, including typical and
atypical antipsychotic drugs (Andree et al., 1986), typical and
atypical antidepressants (Blackshear and Sanders-Bush,
1982; Brunello et al., 1982), and even relatively selective
5-HT2A antagonists (Leysen et al., 1986). There have also
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been reports that some 5-HT2A antagonists can up-regulate
5-HT2A receptors after chronic administration (Rinaldi-Car-
mona et al., 1993) or have no effect (Gray and Roth, 2001).
Antagonist-induced 5-HT2A down-regulation might have
therapeutic relevance (Elphick et al., 2004; Harvey et al.,
2004; O’Connor and Roth, 2005). We now know that antago-
nist-induced receptor down-regulation can be readily ex-
plained by the concept of functional selectivity (Urban et al.,
2007) or biased agonism (Roth and Chuang, 1987; Galandrin
et al., 2007).
The mechanism(s) responsible for the paradoxical antago-
nist-induced receptor “down-regulation” are still unclear.
Several studies have demonstrated that 5-HT2A antagonists
can induce receptor internalization in vitro (Berry et al.,
1996; Willins et al., 1999; Bhatnagar et al., 2001) and in vivo
(Willins et al., 1998, 1999). In addition, receptor down-regu-
lation is apparently independent of changes in receptor gene
transcription (Roth and Ciaranello, 1991). Two independent
studies have indicated that antagonist-induced internaliza-
tion occurs via clathrin-dependent processes in vitro (Bhat-
nagar et al., 2001; Hanley and Hensler, 2002).
In addition, although there have been a large number of
reports of antagonist-induced down-regulation of 5-HT2A re-
ceptors, all prior studies have relied on radioligand binding
to quantify changes in total receptor protein. There are a
number of possible explanations for alterations in radioli-
gand binding after drug administration that could account
for changes in receptor protein levels independent of receptor
down-regulation (e.g., residual drug, pseudo-irreversible
binding, and receptor inactivation). Ideally, one would like to
be able to quantify 5-HT2A receptor protein via a conven-
tional biochemical technique (for instance, Western blotting)
to begin to definitively address the question of antagonist
functional selectivity.
It has long been known that available 5-HT2A antibodies
are neither sufficiently specific nor sensitive for biochemical
studies in vivo (Xia et al., 2003). In recent studies, however,
we identified and validated a 5-HT2A receptor antibody in
wild-type and 5-HT2A knockout mice and showed that it was
suitable for immunochemical and biochemical studies
(Magalhaes et al., 2010; Yadav et al., 2011). Similar results
were reported by another group (Weber and Andrade, 2010).
Using this new reagent, we are now able to report that
5-HT2A antagonists differentially regulate 5-HT2A receptor
protein levels in vivo. In addition, we are able to identify
three classes of 5-HT2A antagonists: those that induce recep-
tor down-regulation, those that induce receptor up-regula-
tion, and those that have no effect on receptor protein levels.
Materials and Methods
Mice. Male C57BL/6J mice were either obtained from The Jack-
son Laboratory (Bar Harbor, ME) or bred for two to three genera-
tions in-house to obtain a sufficient number of male mice (24–30)
between 8 and 10 weeks of age to test drugs. All experiments were
approved by the Institutional Animal Care and Use Committee at
the University of North Carolina, Chapel Hill. Mice were housed
under standard conditions: 12-h light/dark cycle and food and water
ad libitum.
Drugs. Clozapine [8-chloro-11-(4-methyl-1-piperazinyl)-5H-
dibenzo[b,e][1,4]diazepin] and olanzapine [2-methyl-4-(4-methyl-1-
piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine] were purchased
from Sigma-Aldrich (St. Louis, MO), and haloperidol [(4-[4-(4-
chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone
hydrochloride)] was obtained from Sigma/RBI (Natick, MA). Ketanserin
[3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-2,4[1H,3H]-quinazolin-
edione tartrate], altanserin [3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]
ethyl]-2,3-dihydro-2-thioxo-4(1H)-quinazolinone hydrochloride], and
-phenyl-1-(2-phenylethyl)-4-piperidinemethano (M11939) were pur-
chased from Tocris Bioscience (Ellisville, MO). -(2,3-Dimethoxyphe-
nyl)-1-[2-(4-fluorophenylethyl)]-4-piperidine methanol (M100907) and
4-[(2Z)-3-{[2-(dimethylamino)ethoxy]amino}-3-(2-fluorophenyl)prop-2-
en-1-ylidene]cyclohexa-2,5-dien-1-one (SR46349B)was obtained from
sanofi-aventis (Bridgewater, NJ). Pimavanserin was kindly provided by
Dr. Herb Meltzer (Department of Psychiatry, Vanderbilt University,
Nashville, TN).
Chronic Drug Treatment and Behavior Testing Regimen.
C57/BL6 mice (8–10 weeks old) were first tested for short-term
vehicle (0.9% NaCl solution)- or phencyclidine (PCP) (6.0 mg/kg
i.p.)-induced locomotor response. After 8 to 10 days of washout, the
same cohort of mice were used for long-term drug treatments (one
injection/day between 2:00 and 4:00 PM for 14 days) either with
vehicle (5 ml/kg solution containing 0.9% NaCl, 50 mM tartaric acid
and1% dimethyl sulfoxide) or with M100907 (5.0 mg/kg) or M11939
(5.0 mg/kg) or SR46349B (5.0 mg/kg) or ketanserin (10.0 mg/kg),
altanserin (10.0 mg/kg), or pimavanserin (5.0 mg/kg) or clozapine
(10.0 mg/kg) or olanzapine (10.0 mg/kg) or haloperidol (0.5 mg/kg).
The dosage of each drug used in this study was decided on the basis
of literature doses to induce a regulatory adaptation of 5-HT2A re-
ceptors (Gray and Roth, 2001) or the maximal tolerated doses that
are in excess of those shown previously to induce antipsychotic-like
activity. Thus, the doses of M100907 and M11939 chosen (5 mg/kg)
exceed the maximal effective doses used in behavioral studies (0.1
mg/kg for M100907 and M11939) (Costall and Naylor, 1995; Martin
et al., 1997). Likewise, for ketanserin, the dose chosen (10 mg/kg)
Fig. 1. Dose-dependent down-regulation of 5-HT2A receptor by clozapine.
Top, C57BL/6J mice were treated with vehicle (Veh) or clozapine (Cloz)
(2.5–10.0 mg/kg i.p.) for 14 days, and 5-HT2A receptor levels were deter-
mined by immunoblotting (IB) of WGA immunoprecipitates (IP) from
frontal cortex membrane lysates (top panel). The same blots were
stripped and probed for transferrin receptor as loading controls (bottom
panel). Bottom, quantitation of immunoblots by densitometry of 5-HT2A
immunoreactivity (n  4 mice/treatment group). MW, molecular weight.
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exceeds the effective dose for normalization of MK801-induced hy-
peractivity (0.12 mg/kg) (O’Neill et al., 1998) and was the maximal
tolerated dose for this drug. For altanserin, we chose a dose of 10
mg/kg, which was the maximal tolerated dose and in excess of that
previously used for behavioral studies of 5-HT2A receptors (0.5 mg/
kg) (Stoessl et al., 1990). For pimavanserin, the dose chosen (5
mg/kg) was the maximal tolerated dose and again exceeded the dose
used previously in behavioral studies (3 mg/kg) (Horiguchi et al.,
2011). To determine the chronic effects of drug on PCP-induced
locomotor response, 12 to 14 h after the last drug administration, the
same cohort of mice were challenged with PCP (6.0 mg/kg i.p.), and
locomotor responses were measured. Furthermore, mice were eutha-
nized right after locomoter testing, and cortical tissue were isolated
for the measurement of 5-HT2A receptor levels.
Radioligand Binding Assays. For saturation binding assays,
brain regions were rapidly microdissected, frozen on dry ice, and
then stored at 80°C. A Tissue-Tearor (BioSpec Products, Bartles-
ville, OK) was used to homogenize tissue (15 s, 15,000 rpm) in
ice-cold standard binding buffer (SBB) (50 mM Tris-HCl, pH 7.4, 10
mM MgCl2, and 0.1 mM EDTA). Homogenized tissue was centri-
fuged for 20 min at 27,000g (4°C); crude membrane pellets were
collected and washed two more times in a total of 20 ml of ice-cold
SBB. After the last wash, the membrane pellet was either used
immediately for binding or stored at 80°C until use. Saturation
binding assays were performed with the homogenized brain tissue
and [3H]ketanserin and then incubated in SBB for 1.5 h as detailed
(Abbas et al., 2009). Nonspecific binding was determined by incubat-
ing the reactions with 10 M ritanserin. Reactions were harvested
by vacuum filtration through glass filters (3 ice-cold 50 mM Tris,
pH 7.4; pH 6.9 at room temperature) and measured by liquid scin-
tillation using a Tri-Carb 2800TR scintillation counter (PerkinElmer
Life and Analytical Sciences, Waltham, MA). Nonlinear saturation
Fig. 2. Chronic clozapine and olanzapine
but not haloperidol down-regulate 5-HT2A
receptor and attenuate PCP-induced hyper-
locomotor responses in C57BL/6J mice.
A, immunoblot (IB) of immunoprecipitates
from cortex membrane lysates. The same
blots were stripped and probed for transfer-
rin receptor as loading controls. B, densi-
tometry of immunoblots (n  6 mice/treat-
ment group; , p  0.05 by unpaired t test).
C, representative saturation isotherms ob-
tained by binding of [3H]ketanserin with
equal amounts of cortical membrane pro-
teins (25 g) from vehicle (Veh) or clozapine
(Cloz) or olanzapine (Olanz) or haloperidol
(Hal) treatment groups. D, Bmax estimates
were obtained by performing [3H]ketan-
serin saturation binding on cortical mem-
brane homogenates. Data are presented as
mean  S.E.M. (n  6/group; , p  0.05
unpaired t test). E–H, chronic treatments
with clozapine or olanzapine (10.0 mg/kg,
14 days) significantly attenuated PCP (6.0
mg/kg)-induced hyperactivity, but haloper-
idol (0.5 mg/kg) had no significant effect in
C57BL/6J mice (n  8/group). Data are ex-
pressed as mean total horizontal distance
traveled in 5-min bins over 60 min after
PCP administration (S.E.M.). , p  0.05,
two-way analysis of variance, followed by
Bonferroni post-tests for multiple compari-
sons. MW, molecular weight.
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analysis was done with GraphPad Prism 4.01 (GraphPad Software
Inc., San Diego, CA) to obtain Bmax values, and Bradford protein
assays (Bio-Rad Laboratories, Hercules, CA) were performed to nor-
malize Bmax determinations to the amount of protein in each assay.
Western Blotting. For 5-HT2A receptor immunoblotting, frontal
cortex crude membrane preparations were resuspended in cold lysis
buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 10% glycerol, 1%
NP-40, 0.5% sodium deoxycholate, and 0.1% SDS, plus protease
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) and incu-
bated on ice for 1 h. Detergent-soluble proteins were collected after
20 min of centrifugation at 4°C and 12,500g, and 500 g (1.0 mg/ml)
of protein was incubated with 25 to 30 l (packed volume) of wheat
germ agglutinin (WGA)-conjugated agarose beads (Vector Laborato-
ries, Inc., Burlingame, CA) for a minimum of 2 h at 4°C on a rotary
mixer. After three washes with 500 l of lysis buffer, WGA-bound
proteins were eluted with 40 l of 1 SDS sample buffer, and whole
eluates were resolved by SDS-polyacrylamide gel electrophoresis,
followed by electrotransfer of protein from gel to polyvinylidene
difluoride membrane. Membranes were blocked for 1 h using buffer
containing 3% nonfat dry milk, 1% bovine serum albumin, and 5%
glycerol in Tris-buffered saline-Tween 20. Rabbit polyclonal anti-5-
HT2A receptor antibody (Neuromics, Edina, MN) was used at a 1:500
dilution for 12 to 18 h at 4°C for measurement of 5-HT2A receptor
immunoreactivity. For a loading control, the same membrane was
stripped and reprobed with anti-transferrin receptor mouse mono-
clonal antibody (Invitrogen, Carlsbad, CA). We have previously ver-
ified the specificity of the anti-5-HT2A receptor antibody using
5-HT2A wild-type and knockout mouse cortex tissue by immunoblot-
ting (Magalhaes et al., 2010).
Locomotor and Stereotypic Activity. Locomotor activity was
assessed in photocell-based activity chambers under standardized
environmental conditions, using an AccuScan activity monitor
(AccuScan Instruments, Columbus, OH) with a 25.8  25.8 cm
Plexiglas chamber and a beam spacing of 1.52 cm as described
(Abbas et al., 2009). Mice received intraperitoneal injections of vehi-
cle (0.9% NaCl solution) or PCP (6 mg/kg, dissolved in saline solu-
tion) after 20 to 30 min of habituation in activity chambers followed
by measurement of horizontal activity for 60 to 90 min. Horizontal
activity was measured as the total distance covered in centimeters as
the total of all vectored X-Y coordinate changes.
Statistical Analysis. For quantitation of immunoblots, compar-
ison of Bmax data, and other two-group comparisons, two-tailed un-
paired t tests were used to ascertain statistical significance. All
behavioral data were analyzed by two-way analysis of variance fol-
Fig. 3. Chronic administration of 5-HT2A
selective antagonists M100907 or M11939
did not modulate 5-HT2A receptor level and
PCP-induced hyperlocomotor response in
C57BL/6J mice. A, immunoblot (IB) of im-
munoprecipitates (IP) from cortex mem-
brane lysates. The same blots were stripped
and probed for transferrin receptor as load-
ing controls. B, densitometry of immuno-
blots of immunoprecipitates from n  4
mice/treatment group. C, Bmax estimates
were obtained by performing [3H]ketan-
serin saturation binding on cortical mem-
brane homogenates. Data are presented as
mean  S.E.M. (n  6/group). D–F, chronic
treatments with vehicle (Veh) or M100907
or M11939 (5.0 mg/kg, 14 days) had no sig-
nificant effect on PCP (6.0 mg/kg)-induced
hyperactivity in C57BL/6J mice (n 
7/group). Data are expressed as mean total
horizontal distance traveled in 5-min bins
over 60 min after PCP administration
(S.E.M.). MW, molecular weight.
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lowed by Bonferroni post-tests for comparing multiple groups. Com-
parisons were considered significant if p  0.05.
Results
Olanzapine and Clozapine but Not Haloperidol Down-
Regulate 5-HT2A Receptors. In initial studies, we performed
dose-response experiments to investigate the ability of the atyp-
ical antipsychotic drug clozapine to induce cortical 5-HT2A re-
ceptor down-regulation in C57BL/6J mice. To quantify 5-HT2A
receptor protein levels, we used our recently validated Western
blot procedure (Magalhaes et al., 2010; Yadav et al., 2011) along
with parallel radioligand binding studies with [3H]ketanserin.
As can be seen in dose-response studies (Fig. 1), 10.0 mg/kg
clozapine induced maximal down-regulation of 5-HT2A receptor
protein, and thus this dose was chosen for further studies.
We next evaluated three drugs we had previously shown to
induce a differential pattern of receptor internalization in vitro
and in vivo: clozapine, olanzapine, and haloperidol (Willins et
al., 1999). As can be seen, chronic treatment with clozapine and
olanzapine, but not haloperidol, induced a down-regulation of
5-HT2A receptor protein as assessed by both Western blot
(Fig. 2, A and B) and radioligand binding (Fig. 2, C and D)
studies. As is seen in Fig. 2, E to H, chronic olanzapine and
clozapine, but not haloperidol or vehicle, was associated with an
attenuation of the PCP-induced locomotor response.
Selective and Preferential 5-HT2A Antagonists Dif-
ferentially Modulate 5-HT2A Receptor Protein Levels
after Chronic Administration. We next evaluated a series
of selective 5-HT2A antagonists for their ability to induce
5-HT2A receptor down-regulation. As shown in Fig. 3, A to C,
chronic treatment with M100907 and M11939 had no effect
on either 5-HT2A receptor protein or radioligand binding. In
addition, no effect on PCP-induced locomotor responses was
seen (Fig. 3, D–F).
In contrast, the prototypical 5-HT2A antagonist ketan-
serin, but not the closely related compound altanserin, in-
duced 5-HT2A receptor protein down-regulation (Fig. 4, A–C).
Chronic treatment with these compounds had no significant
effect on PCP-induced locomotor responses (Fig. 4, D–F).
We next tested two 5-HT2A antagonists that have been
shown in small-scale trials to have efficacy in treating psy-
chosis, SR46349B (Meltzer et al., 2004) and pimavanserin
(Meltzer et al., 2010). In the case of SR46349B, an up-regu-
lation of 5-HT2A receptor protein was noted, whereas chronic
pimavanserin treatment had no effect (Fig. 5, A–F). These
results indicate that reasonably selective 5-HT2A antagonists
may display strikingly different effects on receptor protein
Fig. 4. Chronic administration of the 5-HT2A
antagonist ketanserin (Ket) but not altanserin
(Alt) down-regulates the cortical 5-HT2A recep-
tor level in C57BL/6J mice. A, measurement of
5-HT2A receptor level in frontal cortex mem-
brane lysates by immunoblotting (IB) of immu-
noprecipitates (IP). The same blots were re-
probed for transferrin receptor as loading
controls. B, densitometry of immunoblots of
immunoprecipitates from n  4 mice/treat-
ment group. , p  0.05, unpaired t test.
C, Bmax estimates were obtained by performing
[3H]ketanserin saturation binding on cortical
membrane homogenates. Data are presented
as mean  S.E.M. (n  6/group). D–F, chronic
treatment with vehicle or ketanserin or altan-
serin (10.0 mg/kg, 14 days) had no significant
effect on PCP (6.0 mg/kg)-induced hyperactiv-
ity in C57BL/6J mice (n  8/group). Data are
expressed as mean total horizontal distance
traveled in 5-min bins over 90 min after PCP
administration (S.E.M.). MW, molecular
weight; Veh, vehicle.
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levels: up-regulation (SR46349B), down-regulation (ketan-
serin), or no effect (M100907, altanserin, pimavanserin, and
M11939). SR46349B-mediated up-regulation was associated with
a potentiation of PCP-induced locomotor responses (Fig. 5G),
whereas chronic pimavanserin treatment had no effect (Fig. 5H).
Discussion
The main finding of these studies is that 5-HT2A receptor
antagonists can be classified into three major categories on the
basis of their differing abilities to regulate 5-HT2A receptor
protein expression: 1) up-regulating antagonists (SR46349B),
2) down-regulating antagonists (ketanserin, clozapine, and
olanzapine), and 3) antagonists that do not alter receptor ex-
pression in male C57BL/6J mice at the doses used in this study
(M100907, M11939, pimavanserin, and altanserin). We also
report that the SR46349B-induced receptor up-regulation is
associated with an apparently augmented PCP-induced locomo-
tor response. Although it has been widely reported that 5-HT2A
antagonists display differential abilities to induce alterations in
5-HT2A receptor radioligand binding, this is the first study
demonstrating an actual change in 5-HT2A receptor protein
levels after chronic drug administration.
For many years, it has been suggested that 5-HT2A down-
regulation might be associated with the therapeutic actions
of many drugs (Gray and Roth, 2001; Elphick et al., 2004;
O’Connor and Roth, 2005). Indeed, down-regulation of
5-HT2A receptors is probably part of the mechanism by which
certain 5-HT2A antagonists apparently protect against JC
virus infections (Elphick et al., 2004; O’Connor and Roth,
2005). It has also been suggested that 5-HT2A receptor down-
Fig. 5. Chronic administration of the
5-HT2A selective inverse agonist SR46349b,
but not pimavanserin, up-regulates 5-HT2A
receptor level but had no significant effect on
PCP-induced hyperlocomotor response in
C57BL/6J mice, A and B, immunoblot (IB) of
immunoprecipitates (IP) from cortex mem-
brane lysates. The same blots were reprobed
for transferrin receptor as loading controls. C
and D, densitometry of immunoblots of im-
munoprecipitates from n  4 mice/treatment
group. , p  0.05, unpaired t test. E and
F, Bmax estimates were obtained by perform-
ing [3H]ketanserin saturation binding on cor-
tical membrane homogenates. Data are pre-
sented as mean  S.E.M. (n  6/group),
, p  0.05, unpaired t test. G and H, chronic
treatment with vehicle or SR46349b or pima-
vanserin (5.0 mg/kg, 14 days) had no signifi-
cant effect on PCP (6.0 mg/kg)-induced hyper-
activity in C57BL/6J mice (n  6–8/group).
Data are expressed as mean total horizontal
distance traveled in 5-min bins over 90 min
after PCP administration (S.E.M.). , p 
0.05, unpaired t test. MW, molecular weight;
Veh, vehicle.
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regulation itself might contribute to atypical antipsychotic
drug actions. Indeed, as this article clearly shows, chronic
treatment with clozapine and olanzapine, two prototypical
atypical antipsychotic drugs, induces substantial down-reg-
ulation of 5-HT2A receptor protein. This down-regulation was
associated with an attenuated ability of PCP to induce a
locomotor response. In contrast, chronic treatment with the
typical antipsychotic drug haloperidol was without effect on
either PCP-induced locomotion or 5-HT2A receptor levels.
Of interest, chronic treatment with three candidate anti-
psychotic drugs (M100907, SR46349B, and pimavanserin)
either had no effect (M100907 and pimavanserin) or up-
regulated 5-HT2A receptors. It is interesting in this regard
that not only did none of these drugs attenuate the hyperlo-
comotive ability of PCP but also none of these drugs dis-
played efficacy in large-scale phase III clinical trials. Taken
together, these findings are consistent with the notion that
down-regulation of 5-HT2A receptors may be important for
certain therapeutic actions of atypical antipsychotic drugs.
However, atypical antipsychotics clozapine and olanzapine
have marked polypharmacology, with affinities for dopa-
mine, serotonin, muscarinic, and adrenergic receptors (Roth
et al., 2004). Thus, it is quite complicated and the subject of
considerable controversy to explain unique salutary effects of
clozapine and other related atypical antipsychotics (Allen
and Roth, 2011). The most important implication of these
findings is the clear-cut evidence in favor of the hypothesis
that antagonists display unique patterns of functional selec-
tivity. The precise molecular mechanisms responsible for the
paradoxical down-regulation of 5-HT2A receptors in vivo are
currently unknown and are the topic of intensive research
at present (P. M. Yadev and B. L. Roth, manuscript in
preparation).
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